658 filings
Page 6 of 33
6-K
nky7ya i7g1tixkb
29 Sep 21
Immutep Receives A$3.4 million R&D Tax Incentive from French Government
6:44am
6-K
3ttrdlq gbum43zf
2 Sep 21
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
6:35am
6-K
1foixdjd randktbwo
1 Sep 21
Preliminary final report
7:22am
6-K
vbj3 ai0msr
31 Aug 21
Current report (foreign)
6:09am
6-K
gwaocfg
27 Aug 21
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
6:08am
6-K
hhbn9gdsnkz5jy244
5 Aug 21
Immutep Reports Dosing of First Patient For Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003
6:05am
6-K
vuko9ddm 258e3avki2x
2 Aug 21
Immutep completes tranche 2 of its previously announced placement
10:01am
6-K
ip6c e677w8
21 Jul 21
Not for release to US wire services or distribution in the United States
6:06am
6-K
6wbsns
13 Jul 21
Immutep Quarterly Activities Report & Appendix 4C
8:31pm
6-K
s5c qd0x6
7 Jul 21
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
12:00am
6-K
hx4nkrfynmv
22 Jun 21
Immutep completes a A$60 million placement to expand its clinical
12:00am
6-K
ff2jze pc3
22 Jun 21
Current report (foreign)
12:00am
6-K
w9yiuf
9 Jun 21
Current report (foreign)
12:00am
6-K
xd2i9uui8
7 Jun 21
Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021
12:00am
6-K
w82hhf
7 Jun 21
Immutep Reports Positive Data from its
12:00am
6-K
1uz0vahp1hx9z
3 Jun 21
Immutep Secures Second European Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, In Combination with a PD-1 Pathway Inhibitor
12:00am
6-K
af8o qunrbld
2 Jun 21
Current report (foreign)
12:00am
6-K
qqum2h olq
27 May 21
Immutep Granted Chinese Patent for Eftilagimod Alpha
12:00am
6-K
3sn92jnfpzsvo8lk
21 May 21
Immutep announces publication of TACTI-002 and INSIGHT-004 abstracts
12:00am